Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

WIN 2012 /
Drugging the cancer genome: opportunities and challenges

28th - 29th Jun 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 16.07.12
Views: 6898
Rating:

Prof Paul Workman - Institute of Cancer Research, UK

“Prof Paul Workman discusses how the Institute of Cancer Research (ICR) is working to speed up the discovery and development of drugs acting on new cancer drug targets.

 

Although cancer genome sequencing and other large-scale efforts are uncovering many potential new treatment targets, these are not always pursued by major pharmaceutical companies due to the high risk associated with early stage research.

 

Prof Workman explains how ICR, as a non-profit academic group, has been able to successfully discover prototype drugs acting on high risk potential targets and progress them to the stage where they can be taken up by pharmaceutical companies.”

 

Filming supported by Amgen

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation